We are a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. (Incorporated in Australia)

A “white label” gel-based delivery solution is where we produce a product that other companies rebrand as their own product. Our principal products are edible gels, which we refer to as gels, and their application in gel-based dosage forms. Our current product suite consists of multiple products that sit within five core verticals — pets, sports, pharmaceutical (pharma), over-the-counter (OTC) and nutraceutical — all of which leverage our patent- pending multiple-ingredient dosage forms, and which we expect to have a wide range of applications and consumers. We currently focus our efforts on out-licensing our technology to companies to develop and create new products they can manufacture and sell within their established and researched markets, while we continue to manufacture our existing products under license (“white label”). 

*Note: For the year that ended June 30, 2022, Gelteq Ltd. reported a net loss of US$2.29 million on revenue of about US$100,000, according to the prospectus.

*Note: Net loss and revenue figures are in U.S. dollars (converted from Australian dollars) for the 12 months that ended June 30, 2023.

*Note: For the year that ended June 30, 2023, Gelteq Ltd. reported a net loss of US$2.28 million on revenue of about US$50,000, according to the prospectus.

(Note: R.F. Lafferty & Co. and Craft Capital Management are the joint book-runners. They replaced Boustead Securities, which was the original sole book-runner.) 

(Note: Gelteq Ltd. is offering 1.3 million Class A ordinary shares at $5.00 to raise $6.5 million – the terms that it disclosed in its F-1 dated Aug. 30, 2022. This is a NASDAQ listing. The Melbourne, Australia-based company filed confidential IPO documents on March 31, 2022.)